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Asbestos-Related Diseases and 
Blood Biomarkers
Alenka Franko, Vita Dolzan, Katja Goricar  
and Metoda Dodic Fikfak
Abstract
Asbestos-related diseases, including asbestosis, benign pleural diseases, lung 
cancer, other types of cancer, and especially malignant mesothelioma (MM), still 
represent an enormous problem all over the world and are among the most investi-
gated occupational diseases. Considering that MM is a highly aggressive and severe 
malignant cancer of pleura, peritoneum and other serosal surfaces, new blood 
biomarkers for earlier diagnosis, following response to treatment and disease pro-
gression, have been intensively investigated. Several studies suggested that soluble 
mesothelin-related peptides, fibulin-3, survivin, osteopontin, vimentin, calretinin, 
and many others could be helpful in diagnosis, detecting the progression of MM 
and evaluating tumour response to treatment; however, these biomarkers have not 
been validated in clinical practice. Therefore, search for novel better stand-alone or 
composite biomarkers is under way. The aim of this chapter is to present the impor-
tance of blood biomarkers in evaluating the risk of developing asbestos-related 
diseases, early diagnosis, following the response to treatment and progression of 
these diseases, with special emphasis on MM.
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1. Introduction
Although the asbestos production and usage have been banned in many coun-
tries, the asbestos-related diseases still represent an enormous public health prob-
lem all over the world [1–3]. Occupational and environmental exposure to asbestos 
fibres has been associated with the development of asbestosis, pleural diseases such 
as pleural plaques, diffuse pleural thickening, pleural effusion, malignant mesothe-
lioma (MM) of the pleura, peritoneum and other serosal surfaces, lung cancer, and 
some other types of malignant diseases, including cancer of the larynx, cancer of 
the ovary, and possibly also cancers of the buccal mucosa, the pharynx, the gastro-
intestinal tract, and the kidney [1–10]. The asbestos-related diseases are considered 
to be among the most investigated occupational diseases [1–3, 7, 8, 10]. In particu-
lar, MM, a highly aggressive cancer, causes serious concerns because of its dismal 
prognosis, poor therapeutic strategies, and fatality [11–13]. Therefore, search for 
novel better stand-alone or composite biomarkers is under way. This is especially 
important for high-risk populations with a known history of asbestos exposure.
The aim of this chapter is to present the importance of blood biomarkers 
in evaluating the risk of developing asbestos-related diseases, early diagnosis, 
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following the response to treatment and progression of these diseases, with special 
emphasis on MM.
2. Blood biomarkers in asbestos-related diseases
It has been proposed that blood biomarkers, such as mesothelin, fibulin-3, 
osteopontin, vimentin, and many others, could enable noninvasive and early detec-
tion of asbestos-related diseases and could be particularly helpful in diagnosing 
MM, detecting the progression of this cancer and evaluating tumour response to 
treatment.
2.1 Mesothelin
One of the most investigated biomarkers in MM is mesothelin, a circulating form 
of a glycoprotein attached to the cell surface, that is considered to have a role in cell 
adhesion, proliferation, invasion, and possibly in cell-to-cell signalling. Mesothelin 
is highly expressed in MM as well as in several other cancers [14–18]. It exists in 
different forms that can be detected in serum in the form of soluble mesothelin-
related peptides (SMRP) by enzyme-linked immunosorbent assay (ELISA) using 
monoclonal antibody techniques [19].Many studies have investigated mesothelin as 
a possible tumour biomarker for diagnosing MM, evaluating response to treatment, 
as well as for detecting the progression of this malignoma [16, 20–26].
Robinson et al. proposed SMRP as a marker for diagnosis and monitoring pro-
gression of the disease [20]. Later, the same group also suggested that SMRP may 
also be useful for monitoring MM progression and may prove useful for screening 
asbestos-exposed individuals for early MM [16].
Different mesothelin-related antibodies were tested in studies to detect differ-
ent forms of mesothelin. Maeda et al. found that the soluble N-terminal fragment 
N-ERC/mesothelin is a very stable and plentiful in the blood [27]. Shiomi et al. 
identified N-ERC/mesothelin as a potential biomarker for MM and used newly 
developed ELISA system to gain data on N-ERC/mesothelin levels in different clini-
cal settings. In their study, serum N-ERC/mesothelin levels showed that the median 
values from MM patients were extremely high as compared to levels obtained 
from other subjects (e.g., healthy volunteers and asbestos-related non-malignant 
 diseases) [28].
Several other studies also reported higher levels of SMRP in subjects with MM 
and proposed that SMRP could be a useful tumour biomarker for diagnosing MM 
and monitoring the disease progression [21–24].
Franko et al. found that pre-treatment SMRP levels were significantly higher 
than in stable disease, partial response, and complete response, as were SMRP 
levels in progressive disease compared to stable disease, partial response, and 
complete response. The findings of this study also suggested that SMRP may be a 
useful tumour marker for detecting the progression of MM and evaluating tumour 
response to treatment [25].
A study of Hollevoet et al. investigated the diagnostic accuracy and use of serum 
mesothelin in early diagnosis by performing an individual patient data meta-
analysis. The results of the study showed that in patients suspected of having MM, a 
positive blood test for mesothelin at a high-specificity threshold presented a strong 
incentive to urge further diagnostic steps. On the other hand, they reported that the 
poor sensitivity of mesothelin clearly limits its added value to early diagnosis [26].
The overall diagnostic accuracy of SMRPs in serum and the pleural fluid was 
also investigated in meta-analysis of Cui et al. [29]. The authors concluded that 
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SMRPs in serum and pleural fluid are helpful biomarkers for diagnosing MM, and 
that they have a similar diagnostic accuracy. However, they stressed that negative 
results of SMRP determinations are not sufficient to exclude MM, while the positive 
test results indicate that further invasive diagnostic steps might be necessary for the 
diagnosis of MM [29].
The meta-analysis by Gillezeau et al. studied the mean differences of mesothe-
lin, osteopontin, and fibulin-3 in blood and pleural samples. A total of 32 studies 
with mesothelin levels were included. Statistically, significant mean differences 
have been found between MM patients and all the other comparison groups for 
mesothelin blood and pleural levels. It has been concluded that based on the find-
ings, mesothelin levels seem to be significantly lower in all control groups compared 
with those with MM, suggesting a possible role of mesothelin as a screening bio-
marker for MM [30].
2.2 Fibulin
Human fibulin-3, also known as epidermal growth factor containing fibulin-like 
extracellular matrix protein 1 (EFEMP1), has also been investigated as a potential 
biomarker for asbestos-related diseases, especially for MM [31–33]. It is a member 
of a family of extracellular matrix glycoproteins [34] that have been proposed to be 
important in the regulation of cell proliferation and migration and to act as tumour 
suppressors or activators in different cancers [34–38]. Fibulin-3 is predominately 
localised in the extracellular matrix of elastic tissue, and it has restricted expression 
in the body [37].
Several studies showed that levels of fibulin-3 expression decreased in several 
types of cancer and were correlated with poor survival of patients with breast can-
cer [39], hepatocellular carcinoma [40], and lung cancer [41, 42]. On the contrary, 
an increase in fibulin-3 was found in cervical carcinomas [43], pancreatic cancer 
[44], and malignant gliomas [45].
Fibulin-3 was first investigated as a potential tumour biomarker of MM in the 
study of Pass et al. who found that plasma fibulin-3 levels can distinguish asbestos-
exposed healthy persons from patients with MM [31]. Their results showed that 
plasma fibulin-3 levels in conjunction with fibulin-3 levels in pleural effusions can 
differentiate MM effusion from other malignant and benign effusions [31].
Several further studies investigated the possible role of fibulin-3 in the diagnosis 
of MM, but the results were not consistent. Kaya et al. proposed that real use of 
serum fibulin-3 was not for prognosis but for diagnosis of MM [46].
Ren et al. performed a systematic review and a meta-analysis of eight studies to 
evaluate the diagnostic value of fibulin-3 in plasma, serum, and pleural effusion. 
They found that the overall sensitivity and specificity for blood fibulin-3 were 0.87 
[95% confidence interval (CI) 0.58-0.97] and 0.89 (95% CI 0.77-0.95), respectively. 
Based on these results, they concluded that fibulin-3 is a useful diagnostic bio-
marker for MM [47]. Similarly, Pei et al. reported that fibulin-3 confers a relatively 
high diagnostic efficacy and could be acceptable as an auxiliary biomarker to aid in 
MM identification [32].
Jiang et al. investigated the utility of fibulin-3 not only for MM but also for 
other asbestos-related diseases, therefore including patients with pleural plaques, 
asbestosis, and MM. The results showed that median plasma fibulin-3 level of 
subjects in the MM group was higher than that in other groups. The results also 
showed that subjects in the asbestosis group had a higher median fibulin-3 level 
compared to those in the control group. Their study proposed that fibulin-3 could 
be a potential biomarker for early screening of MM, but not for other asbestos-
related diseases [33].
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The meta-analysis of Gillezeau et al., which includes nine studies with fibulin-3 
levels, also presented a statistically significant difference in both blood and pleural 
levels of fibulin-3 in MM patients compared with those of all other groups [30].
On the other hand, some other studies suggested that plasma fibulin-3 levels 
have low diagnostic accuracy [48–50]. The study of Creaney et al. identified soluble 
mesothelin as a superior diagnostic biomarker for MM compared to fibulin-3, 
whereas fibulin-3 provided superior prognostic information compared to meso-
thelin [48]. Kirschner et al. reported that plasma fibulin-3 level was significantly 
elevated in MM patients from the Sydney cohort, but not the Vienna cohort; how-
ever, the diagnostic accuracy was low. The data confirmed the potential prognostic 
value of pleural effusion fibulin-3 [49]. The same applies to the study of Ledda et al. 
who reported that fibulin-3 did not show a superior diagnostic performance [51].
The study of Kovac et al. aimed to evaluate the potential applicability of fibu-
lin-3 plasma levels as a biomarker of response to treatment and its prognostic value 
for progressive disease within 18 months. The results of the study showed signifi-
cantly higher fibulin-3 levels in progressive disease in comparison with the levels 
before treatment, in complete response to treatment, and in stable disease, which 
indicated that fibulin-3 could be helpful in identifying the progression of MM. On 
the contrary, no significant difference was observed between the fibulin-3 levels 
before treatment in comparison with the levels in complete response to treatment, 
partial response to treatment, and stable disease. The findings of this study suggest 
that fibulin-3 could be helpful in detecting the progression of MM [52].
2.3 Survivin
Survivin is a member of the inhibitor of the apoptosis protein (IAP) family and 
is known to have a role in the regulation of cell division and apoptosis (programmed 
cellular death). Survivin was first described as an inhibitor of caspase -9. However, 
several studies found that the role of survivin in pathogenesis of malignant diseases 
involves not only apoptosis but also the regulation of the mitotic spindle check-
point, as well as chemoresistance and promotion of angiogenesis. This protein is 
commonly not expressed in normal differentiated tissues; however, it was found to 
be expressed in some cancers. Survivin is related to increased tumour aggressive-
ness, both in pleural fluid and in tissue [53].
Few studies investigated the role of survivin in asbestos-related diseases, or 
more precisely in MM. In their study, Hmeljak et al. performed on tissue samples 
aimed to elucidate whether survivin expression is associated with tumour cell 
proliferation and apoptosis and to investigate the prognostic and predictive value 
of survivin expression in MM. The results indicated that survivin expression might 
contribute to prediction of treatment response. However, the survivin expression in 
pleural MM did not show to have prognostic significance [54].
The only study so far that included blood (serum) samples is the study of 
Goricar et al. who investigated the influence of serum survivin levels on the out-
come of cisplatin-based chemotherapy in patients with MM. The findings suggested 
that serum survivin levels could serve as a biomarker predicting response to treat-
ment in MM before and during chemotherapy [55].
2.4 Osteopontin
Osteopontin is an extracellular cell adhesion protein that is involved in several 
biological processes, including cell-matrix interaction, cell-signalling and migra-
tion, immunological regulation, as well as in tumour development [56–60].
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Elevated levels of serum osteopontin have been found in several cancers, such 
as colon cancer [61], breast cancer [62], lung cancer [63], as well as in MM [64]. 
Accordingly, serum osteopontin has been suggested to be a possible biomarker of 
early detection of MM [64–66].
Pass et al. investigated the presence of osteopontin in pleural MM and deter-
mined serum osteopontin levels in three populations: in asbestos-exposed subjects 
without cancer, subjects without cancer who were not exposed to asbestos, and in 
asbestos-exposed subjects with MM. Based on the results, the authors concluded 
that serum osteopontin levels could be used to distinguish asbestos-exposed 
individuals who do not have cancer from asbestos-exposed individuals with pleural 
MM [65].
The diagnostic performance of osteopontin was investigated in several other 
studies of asbestos-related diseases, but the results were not consistent [67–71].
Paleari et al. investigated the role of plasma osteopontin in diagnosis of pleural 
MM; however, their results suggested that plasma osteopontin levels cannot dis-
criminate between chronic inflammatory and malignant lung disease [67].
The potential role of serum and plasma osteopontin in pleural MM diagnosis 
was reported by Cristaudo et al. [68]. Their results suggested that plasma osteopon-
tin and serum osteopontin are not influenced by confounders such as age, smoking, 
and asbestos exposure. Moreover, plasma and serum osteopontin were proposed to 
be useful biomarkers in the diagnosis of epithelial MM in addition to radiological 
examination [68].
Comparison of plasma versus serum levels of osteopontin in patients with MM 
was performed by Creaney et al., who found that plasma osteopontin has a superior 
diagnostic accuracy to serum [69].
Osteopontin as the diagnostic biomarker was investigated in the cross-sectional 
study. The analysis showed that serum osteopontin levels in MM were higher than 
in benign asbestos-related diseases and healthy exposed subjects [70].
A systematic review and meta-analysis by Hu et al. aimed to evaluate the 
diagnostic accuracy of circulating osteopontin in pleural MM. Based on the analysis 
of six studies, the overall diagnostic sensitivity was 0.65 (95% CI 0.60–0.70) and 
specificity 0.81 (95% CI 0.78–0.85). The authors concluded that osteopontin is an 
effective marker for diagnosis of pleural MM [71].
Regarding peritoneal MM, osteopontin was studied as a potential circulating 
biomarker of diffuse peritoneal MM by Bruno et al. who reported that at multivari-
ate analysis, osteopontin was related with survival. However, the authors concluded 
that osteopontin warrants further investigation as a prognostic marker for diffuse 
peritoneal MM [72].
Considering pleural plaques, Mastrangelo et al. investigated in their study 
whether plasma osteopontin was an indicator of asbestos exposure or effect. Their 
results suggested that osteopontin cannot be a reliable biomarker of asbestos 
exposure or effect (presence of pleural plaques) [73].
2.5 Calretinin
MM diagnosis is usually made at the advanced stages of the disease, which con-
tributes to poor prognosis and short survival of MM patients [74, 75]. To confirm 
MM diagnosis, an immunohistochemical analysis investigating a panel of markers 
on tissue samples is required [75]. Among the positive immunohistochemical MM 
markers that can discriminate between malignant and mesothelial cells with the 
highest sensitivity and specificity are calretinin, cytokeratin5/6, and WT1 [76]. As 
biomarkers that would enable an earlier noninvasive diagnosis of MM are widely 
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studied, recent studies evaluated if soluble calretinin could also be used as a bio-
marker in MM [75, 77–80].
Calretinin is a 30-kDa calcium-binding protein that belongs to the EF-hand 
family [81]. It acts as a calcium-buffering protein and calcium sensor. It plays an 
important role in the neurons, but it is also expressed in the mesothelial cells [81]. 
Calretinin was already shown to promote the invasiveness, proliferation, and migra-
tion of mesothelial cells [82]. It may also be involved in activating the focal adhesion 
kinase (FAK) signalling pathway and epithelial-to-mesenchymal transition [82].
Studies showed that calretinin was increased in plasma and serum of MM 
patients compared to patients with other asbestos-related diseases and healthy 
controls [75, 79, 80]. Interestingly, patients with asbestosis also had slightly higher 
serum calretinin compared to patients with pleural plaques [75]. The ELISA assay 
developed by Raiko et al. is highly sensitive when used to detect calretinin in 
plasma or serum and is robust enough to detect calretinin in retrospective samples 
regardless of storage time [75, 79]. However, as calretinin is mostly expressed in 
epithelioid and biphasic MM, but only in around 30% of sarcomatoid MM [81], its 
usefulness as a soluble biomarker is limited in this histological subtype [75].
Studies also suggest that using a combination of calretinin and mesothelin can 
increase the sensitivity for detecting MM [75, 77]. In asbestos-exposed subjects that 
developed MM, calretinin was increased already in prediagnostic plasma samples 
(even more than a year prior to the clinical diagnosis) compared to asbestos-exposed 
subjects that did not develop MM, especially in samples closer to the diagnosis [77]. 
Even though sensitivity was limited to an individual biomarker, using a combination 
of both calretinin and mesothelin had better predictive ability and could also be 
important as a screening biomarker in asbestos-exposed subjects [77].
2.6 Other biomarkers
Apart from the most frequently studied biomarkers described above, some 
studies investigated other serum or plasma factors in asbestos-related diseases 
[83–85]. Among protein biomarkers, megakaryocyte potentiating factor and high 
mobility group box 1 (HMGB1) were increased in MM patients compared to healthy 
individuals or patients with benign asbestos-related diseases [84, 85].
Additionally, novel studies suggest microRNA (miRNA) expression could also 
serve as a diagnostic or prognostic biomarker in MM [84–86]. Kirschner et al. 
compared cell-free miRNA profiles in plasma from MM patients with healthy 
controls and proposed the potential role of miRNA-29c* and miRNA-92a as a 
candidate tumour biomarkers, and indicated that miRNA-625-3p is a promising 
novel diagnostic marker for MM [86]. Micolucci et al. in their systematic review 
and a quantitative meta-analysis compared the data from asbestos-exposed and 
MM subjects and suggested that the most promising candidates for a multimarker 
signature were circulating miRNA-126-3p, miRNA-103a-3p, and miRNA-625-3p 
in combination with mesothelin [87]. Mozzoni et al. aimed to identify a pattern 
of miRNA (mi-RNA-16, miRNA-17, mi-RNA-126, and miRNA-486) as a possible 
diagnostic biomarker for patients with pleural MM and asbestosis and as prognos-
tic biomarkers for patients with pleural MM. The results showed that all miRNA 
levels were decreased in patients with pleural MM or asbestosis, which has been 
suggested to support the role of circulating miRNAs as potential biomarkers 
for asbestos-related diseases. Additionally, miRNA-16 was directly related to 
prognosis of patients with pleural MM, indicating its possible use as prognostic 
factor in patients with pleural MM [88]. Santarelli et al. performed a study to 
identify miRNAs associated with asbestos-induced malignances. In this study, 
four serum miRNAs (mi-RNA-126, miRNA-205, miRNA-222, and miRNA-520g) 
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were implicated in asbestos-related malignant diseases and could be utilised for 
screening in asbestos-exposed populations [89].
As individual biomarkers that have been proposed in asbestos-related 
diseases have some limitations, it was suggested that a combination of different 
factors might be a better diagnostic or prognostic biomarker in asbestos-related 
diseases [83–85].
3. The role of composite blood biomarkers in asbestos-related diseases
Several studies investigated the potential role of composite blood biomarkers 
in asbestos-related diseases, and many of them included mesothelin together with 
various other biomarkers [72, 90].
Felten et al. assessed the influence of age and asbestos exposure on the blood 
levels of the proposed tumour markers, mesothelin, and osteopontin and deter-
mined the change of these markers over time. The results showed that age had a 
strong influence on biomarker levels. On the other hand, there was no associa-
tion between asbestos exposure duration or benign asbestos-related diseases and 
biomarker levels. The researchers concluded that fixed cut-off values for deciding 
between intensive clinical work-up and continued surveillance appeared inadequate 
for evaluating markers [91].
In addition to evaluating the potential applicability of fibulin-3 plasma levels as 
a biomarker of response to treatment and progression of disease, the study of Kovac 
et al. also assessed the potential applicability of fibulin-3 in comparison with or in 
addition to SMRP. The results indicated that in addition to SMRP, fibulin-3 could 
also be useful in detecting MM progression [52].
Bonotti et al. evaluated the usefulness of SMRP, plasma osteopontin, and 
vimentin as markers of the clinical response to treatment in patients suffering from 
epithelioid MM. In their study, SMRP, osteopontin, and vimentin showed statisti-
cally significant differences between the disease categories: stable disease, partial 
response, and disease progression. Based on the results, it has been concluded 
that the time course of SMRP and vimentin was strongly associated with disease 
status, and so was the time course of osteopontin, although to a lesser extent. The 
researchers suggested that these markers appear to be particularly effective in cases 
of partial response and disease progression, even though their possible use in stable 
disease should be better elucidated [90].
In a recent study that evaluated soluble mesothelin, calretinin, and megakaryo-
cyte potentiating factor, the use of composite of these biomarkers improved the 
performance for diagnosis of pleural MM compared to population controls [78]. 
The combination of calretinin and megakaryocyte potentiating factor had the high-
est sensitivity in men, while the combination of calretinin and mesothelin had the 
highest sensitivity in women [78].
In an Italian cohort, the diagnostic performance of fibulin-3 against SMRP 
was compared in patients with pleural effusion from MM. The results of the study 
showed that the levels of fibulin-3 were similar in pleural effusions from pleural 
MM and pleural effusion from other pathologies in contrast to SMRP levels, which 
were significantly higher in pleural effusion from pleural MM. A further analysis 
confirmed that SMRP showed a good performance, whereas fibulin was not able to 
discriminate pleural MM from other pathologies. The conclusion was that fibulin 
detection in pleural effusion, contrary to SMRP detection, is not useful as a bio-
marker for the diagnosis of pleural effusion from pleural MM [92].
Bruno et al. assessed the diagnostic and prognostic values of mesothelin, 
osteopontin, CEA, CA19-9, CA125, and CA15-3 in diffuse peritoneal MM and 
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other peritoneal malignancies. The conclusion was that when assessing peritoneal 
surface malignancies of unknown origin, elevated mesothelin with low CA19-9 may 
increase the suspicion index for diffuse peritoneal MM. As for the role of osteopon-
tin, further research is needed [72].
4. Conclusions
Considering that asbestos-related diseases, and in particular MM, still repre-
sent a huge health problem and economic burden, the investigation of potential 
biomarkers for evaluating the risk for developing asbestos-related diseases, earlier 
diagnosis of asbestos diseases, evaluating respond to treatment and progression of 
these diseases, is of great importance. Biomarkers for assessing risk of developing 
asbestos diseases are of considerable significance especially in high asbestos-
exposed populations. As presented in the chapter, the results of the studies are not 
consistent, therefore further research is needed to clarify inconsistency and find 
reliable biomarkers that could be used in clinical practice and would enable better 
outcome of asbestos-related diseases and increase survival in MM.
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